video-tag-article">
NEW YORK (dpa-AFX) – New records are set for the US technology exchange Nasdaq on Friday. In contrast, the standard value indices are still lacking momentum to overcome the previous highs.
Over half an hour before trading began, the broker IG assessed the technology-heavy Nasdaq 100 index 0.50 percent higher to 16,565 points. On a weekly basis, it is heading towards a plus of over two percent, and since the beginning of the year there has even been a hefty price gain of almost 29 percent.
In contrast, IG assessed the Dow Jones Industrial on Friday 0.54 percent lower to 35,677 meters, which is a weekly minus of more than one percent, but an annual increase of almost 17 percent.
Bei Foot Locker the investors had to after the recent soaring and business figures can cope with a pre-market price loss of over six percent. The sports retailer was able to increase sales on comparable retail space in the third quarter compared to the previous year. The net result collapsed, however. In addition, the CFO assumes that the global supply chain problems will continue to make themselves felt in the final quarter.
Also at the semiconductor company Applied Materials the market was on the safe side after the record hunt for the shares and initially sold them: The price fell by almost six percent. In addition, analysts were disappointed with the business development in the past quarter and the outlook for the current quarter. The fact that, according to the unanimous assessment, supply chain problems were primarily responsible for this and that demand is still high, did not help the titles.
The shares of the major oil companies continued to suffer from the fall in the price of an important commodity: chevron and Exxon Mobil
became cheaper by more than two percent each time.
In contrast, Moderna titles benefited with a price jump of five and a half percent that the US drug agency FDA corona booster vaccinations with the vaccine of the American Biontech competitor
approved. Its shares, which are listed in New York, showed a plus of a good two percent. According to the company, the FDA has promised an accelerated approval process for a skin cancer vaccine candidate from Mainz if clinical studies are successful./gl/mis
ISIN US2605661048 US7170811035 US6311011026
AXC0211 2021-11-19/15:13
Copyright dpa-AFX Wirtschaftsnachrichten GmbH. All rights reserved. Redistribution, republication or permanent storage without the express prior consent of dpa-AFX is not permitted.
– .
